Researchers of the University of Calgary in Canada, suspect that the novel Coronavirus (SARS-CoV-2) might be in evolution among humans since around 2013. But it might not be the same strain that is causing this COVID-19 pandemic.

Six strains of Coronavirus wereCoronavirus commonly prevalent among animals. But the seventh strain is an anonymous strain that is wreaking havoc in the form of COVID-19 and causing a global catastrophe by infecting the human population in the mass.

While scientists throughout the world are working hard to figure out the virus, its effects, origin, and cure, the World Health Assembly had passed a resolution to find the source of the strain.

There are multiple theories of origin. One, the virus got transferred from an animal to a human. Two, it was artificially developed in a laboratory in china for some medical reasons. However, studies rule out this possibility by saying the origin is natural and not human-made.

Recently, a team of researchers at the University of Calgary in Canada say that the SARS-CoV-2 might have been in circulation among humans beginning from as early as 2013. However, it would not be the same strain responsible for the pandemic. They have submitted their report at the Biorxiv, but the findings of the research have not yet been reviewed by the peers.

It is upon the survival mechanism of the viruses that they keep evolving with the changes with the host organism, i.e., if the host evolves, the virus evolves too. So, when the virus jumped from an animal to human, it would nave underwent genetic modification that would produce a new strain of the same virus, only that now it is more powerful and infective. This implies the virus that had mild or no effect on the animal host may have enormous impacts on the human host. For example, the strain of the virus in the bats did not affect the bats, as their immune system was equipped to co-exist with the virus. However, once it jumped hosts, we obviously tend to fall sick.

What does the Canadian Study say?

The study was conducted by the University of Calgary in Canada between 30 December 2019 to 20 March 2020, when they collected about 479 genome sequences of the novel Coronavirus to study its phylogeny. Phylogeny is the study of the evolutionary development of the virus and its relation to other closely related viruses.

The researchers examined the spike protein of the strain of SARS-CoV-2 and how it attaches to the receptors in the human body. This attachment of the novel Coronavirus and the receptors to the human cells determine how the virus invades the healthy tissues. They found 16 variant strains of the virus and about 11 missense mutations out of the 479 genomes. A mutation is when a single nucleotide change makes the DNA/RNA code for a different protein. Thus, some of them gave rise to a separate phylogenetic tree.

Another one of their findings included that the SARS-CoV-2 might be a combination of both bat virus and the pangolin virus. The study found that the genome of novel coronavirus matched 96 percent with that of bat virus and 90 percent with that of the pangolin virus. They predict that this variant might have developed due to a co-infection in the host.

To trace the origin of this novel Coronavirus, the researchers created an ancestral sequence of the receptor-binding domain (RBD) of the spike protein of SARS-CoV-2 and labeled it N1. RBD is the part of the spike protein that actually binds with the receptor. The animal virus, which is the common ancestor, was labeled N0.

With what they discovered in the experiment, the scientists concluded that the binding affinity of SARS-CoV-2 might not be a determinant of its infectivity. Further, they predict that there should be some other factors that increased their infectivity in humans. The main conclusion is that the ancestral virus could have been infecting humans too, but with unnoticeable symptoms.

The world is waiting for Vaccines to cure the Corona infection; all the medical institutes and pharmaceutical companies are working hard to develop a vaccine. We are happy to announce that Patanjali developed a medicine that shows positive results on Covid-19 Patients. Many companies are conducting clinical trials, completing all the clinical trials on 280 patients across the country. Apart from this, there is no other alternative method and no evidence to cure of the Corona.

Yoga Guru Baba Ramdev launched an Ayurvedic Medicine “Coronil” this medicine will help to treat the Covid-19 infection. Today, (on Tuesday) Ramdev launches this Coronil at Patanjali Yogpeeth in Haridwar, Uttarakhand. The Coronil tablet, launched in a live program by Baba Ramdev.

This Coronil medicine was developed by Patanjali Research Institute, and this medicine was developed by Patanjali Research Insitute in partnership with the National Institue of Medical Science(NIMS), Jaipur. Almost 500 members are worked tirelessly to find medicine for coronavirus. In the live program, he said that the patients who are taken this Coronil would get negative results within four days. These tablets made from the Ashwagandha, Giloy, and Tulsi mixture.

Coronil and Swasari is the first and foremost ayurvedic medication in the world with all evidence to cure COVID-19. Acharya Balkrishna, Chief Executive Officer (CEO) of Patanjali, said earlier this medicine would cure 1000 patients in 5-14 days. And it shows a 100% cure. And he was present today’s occasion of launch along with some other officials.

Patanjali launches the drug which was used to cure of the Corona Pandemic. And this Coronil drug ‘Coronil and Swasari’ recover the COVID-19 infected patients in a week. And this drug was named Divya Coronil Tablet. In the view of Corona, cases increasing day by day in the world, Patanjali launched the Corona Kit on Tuesday. This medicine strengthens the immunity of the patient. The patient should take this Giloy and Tulsi twice a day – morning and evening.

Ramdev declared that they are providing Coronil and Swasari. They conducted two clinical trials to know how medicine works on the human body. The first clinical study was done in Delhi, Ahmedabad, and other places. A total of 280 patients participated in specific trails, and 100 percent of patients were recovered from the COVID-19 within a week. This Coronil kit will be given for 30 days, and the cost of this drug was just Rs 600. However, Patanjali company said that they are going to give this for free for the people who are living below the poverty line.

It was recently found that neurological symptoms are most common in patients suffering from COVID-19. Apart from the respiratory system, the deadly virus affects the nervous system.

The researchers of Northwestern University Feinberg School of Medicine and the University of Colorado School of Medicine have identified mild neurological symptoms like weakness, headaches, dizziness, decreased alertness, weakness, muscle pain, difficulty concentrating, and loss of smell and taste to more severe symptoms like stroke and seizure in the hospitalized coronavirus patients. These symptoms may even begin to show before the usual symptoms like cold, fever, etc., warned Dr. Igor Koralnik, Northwestern Medicine chief of neuro-infectious diseases and global neurology.

According to a journal published in Annals of Neurology, the infection affects the spinal cord, brain, muscles, and nerves in several other ways apart from directly manifesting them. It affects the lung such that the passage of oxygen is blocked, leading to clotting of blood in the heart, as a result of which seizure occur. Another method of manifestation is through inflammation by the immune system.

As this is a pandemic, with the virus spread across the globe, scientists are working on discovering a drug or vaccine that helps overcome the neurological manifestations of the COVID-19 infection, says the journal.

Though around 50 percent of the hospitalized patients showed neurological manifestation, the severe symptoms like seizures were only seen in 0.5%. About 17 percent of the patients suffered dizziness, 13 percent had headaches, 7.5 percent had impaired consciousness, 3 percent showed acute cerebrovascular disease ( It is a disorder that affects the blood vessels and blood supply to the brain), 0.5 percent experiencing ataxia (the loss of full control of bodily movements).

However, long term neurological effects of the virus are yet to be unveiled. Studies are going on with the hospitalized patients to find if these are temporary symptoms or permanent.